First in Human Study of T3P-Y058-739 (T3P)

NCT05120596 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: Pembrolizumab+T3P-Y058-739
DRUG: T3P-Y058-739 (IV)
DRUG: T3P-Y058-739 (IT)

Sponsor

T3 Pharmaceuticals AG